• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Mylan

Mylan

Mylan NV MYL 2 Star

Last Price$69.66Day Change (%)-0.40%
Open Price$70.02Day Change ($)-0.28
Day Range69.49–70.5552-Week Range44.80–76.68

As of Fri 5/22/2015 5:00:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  5. Research
  1. Mylan Confirms First-to-File Patent Challenge Relating to Minivelle®

    Mylan Confirms First-to-File Patent Challenge Relating to Minivelle®

  2. Mylan Launches Gilead Sciences' Sovaldi® Tablets in India

    Mylan Launches Gilead Sciences' Sovaldi® Tablets in India

  3. Mylan Launches Generic Seasonale® Tablets

    Mylan Launches Generic Seasonale® Tablets

  4. Mylan adjusted income is one cent short of views

    Mylan adjusted income is one cent short of views

  5. Mylan Launches Generic Sofosbuvir Tablets, MyHep™, in India

    Mylan Launches Generic Sofosbuvir Tablets, MyHep™, in India

  6. Perrigo rejects new bid offer from Mylan

    Perrigo rejects new bid offer from Mylan

  7. On heels of rejection, Mylan gets letter from Teva

    On heels of rejection, Mylan gets letter from Teva

  8. Mylan ups the ante for Perrigo with $33 billion bid

    Mylan ups the ante for Perrigo with $33 billion bid

  9. Rate Hikes? Not in 2015

    Watson Pharmaceuticals WPI scored big Tuesday when the Food and Drug Administration approved the firm's generic fentanyl patch. We may modestly increase our fair value estimate for Watson and will maintain our fair value estimate for competitor Mylan Laboratories MYL . The pain patch is one of the ...

  10. What Migration Can (and Can’t) Do for a Country’s GDP

    Mylan Laboratories MYL reported impressive second-quarter results Wednesday. However, most of the improvement was temporary and will not affect our fair value estimate. The quarter was only slightly better than we expected after excluding a one-time litigation payment and proceeds from a product ...

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.